N/A
N=78
Assessing and Promoting Resilience in Patients With Adult Congenital Heart Disease
Congenital Heart Disease
Bottom Line
View on ClinicalTrials.gov: NCT04738474 ↗Enrolled (actual)
78
Serious AEs
0.0%
Results posted
Oct 2025
Primary outcome: Primary: Feasibility of Enrollment — 40; 38 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Promoting Resilience in Stress Management (PRISM) (Behavioral); Usual Care (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Washington
- Primary completion
- Jul 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Feasibility of Enrollment |
40; 38 | — |
| PRIMARY Feasibility of PRISM |
32; 35 | — |
| SECONDARY Mean Resilience |
30.1; 28.7 | — |
Summary
The purpose of this study is to evaluate the feasibility and preliminary efficacy of the Promoting Resilience in Stress Management (PRISM) intervention in patients with adult congenital heart disease.
Eligibility Criteria
Inclusion Criteria
- adults with moderate or complex ACHD, stages B, C, or D as defined by the 2018 ACHD guidelines
- receive care in our health system
Exclusion Criteria
- diagnosis of another life-limiting illness
- inability to participate in study activities independently and in English
Data sourced from ClinicalTrials.gov (NCT04738474). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.